Biliary Tract Cancer
Conditions
Brief summary
This study is a multicenter, open-label, single-arm phase II study to evaluate efficacy, safety, and pharmacokinetics characteristics of HA121-28 tablets in advanced biliary tract cancer (BTC). A total of approximately 30 subjects with advanced BTC will be enrolled. The subjects will undergo a 3 weeks-on and 1week-off treatment scheme with HA121-28 tablets 600 mg orally once daily in the 28-day cycle until disease progression or intolerable toxic reaction, whichever occurs first.
Interventions
DRUGHA121-28 tablets
HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Be willing to participate in the clinical trial and sign the informed consent; * Histologically/cytologically confirmed unresectable locally advanced or metastatic BTC (including cholangiocarcinoma or gallbladder cancer) with failure of or intolerance to the prior therapy (including disease progression within 6 months after adjuvant chemotherapy) and with at least one measurable lesion based on RECIST 1.1 criteria; * Aged 18 to 75 years (inclusive); * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\ 1; * Routine blood test results must meet the following criteria without blood transfusion within 14 days: 1) Hemoglobin (Hb)≥90 g/L; 2) Absolute neutrophil count (ANC)≥1.5 x 10\^9/L; 3) Platelet count (PLT)≥75×10\^9/L; * Coagulation test results must meet the following criteria: International Normalized Ratio (INR) \<1.5 or Activated Partial Thromboplastin Time (APTT) \<1.5×ULN; * Other laboratory test results must meet all the following criteria: 1) Total bilirubin (TBIL)≤1.5×ULN, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN (TBIL≤3×ULN, ALT and AST≤5×ULN in the subjects with liver metastasis); 2) Serum creatinine≤1.5×ULN；3) Serum albumin≥28g/L; * Male and female subjects of childbearing potential must agree to take effective contraception for the duration of treatment and for 6 months after completion of study drug administration; female subjects must have negative results of serum/urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.
Exclusion criteria
* Subjects with ampullary carcinoma; * Subjects who had participated in other clinical trials and received the treatment within 4 weeks prior to enrolment; * The time interval between the end of the last antitumor treatment and the first administration of HA121-28 tablets \< 4 weeks (for any antitumor treatment, including but not limited to chemotherapy, radiotherapy and targeted therapy), or \< 2 weeks (for local palliative radiotherapy for pain relief or traditional Chinese medicine with approved indications for cancer); * Urine protein≥2+ and urine protein \> 1.0g/24h; * History of other malignancies within the past 5 years prior to enrolment, except for cured cervical carcinoma in situ, non-melanoma skin cancer, superficial bladder tumor, and early esophageal and gastrointestinal cancers that were confined to the mucosal layer and resected under endoscopy; * History of any solid-organ or bone-marrow transplantation (except the transplantation without immunosuppression such as corneal and hair transplantation); * Unremitted toxic reaction\>grade 1 due to any previous treatment at the time of enrollment (except for hair loss and pigmentation) which is considered to influence the safety evaluation; * ECG meets one of the following criteria: 1) QT/QTc interval≥450ms, congenital long QT syndrome (LQTS) or family history of LQTS; 2) any clinically significant abnormalities of rhythm, conduction or morphology in the resting ECG requiring therapeutic intervention; * Left ventricular ejection fraction (LVEF) \<50% in echocardiogram; * Severe concomitant diseases which may have influence on the safety of the subjects or the completion of the study based on the investigator' judgement such as uncontrolled hypertension (systolic pressure ≥150 mmHg or diastolic pressure ≥100 mmHg after treatment); * High risk factors of gastrointestinal diseases such as gastrointestinal perforation and abdominal fistula; * Subjects with spinal cord, meningeal or brain metastasis (except for asymptomatic or stable brain metastasis within 4 weeks prior to administration); * Subjects with hepatopathy meet one of the following criteria: 1) HBsAg positive and HBV DNA \>2000 IU/mL（or \>1×10\^4 copies/mL）; 2) HCV antibody positive and HCV RNA positive; 3) cirrhosis; * HIV antibody positive; * Subjects have history of surgery within 4 weeks prior to administration or have not been recovered from any previous invasive procedure, except for biliary stenting, biliary drainage, etc.; * Not suitable for the study in the investigator's opinion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | Approximately 3.5 years |
Secondary
| Measure | Time frame |
|---|---|
| objective remission rate | Approximately 3.5 years |
| overall survival | Approximately 3.5 years |
| disease control rate | Approximately 3.5 years |
| duration of response | Approximately 3.5 years |
Other
| Measure | Time frame |
|---|---|
| adverse events incidence | Approximately 3.5 years |
| HA121-28 plasma concentration | Approximately 3.5 years |
Countries
China
Outcome results
None listed